Literature DB >> 19203856

Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?

Ingrid E Scheffer1, Yue-Hua Zhang, Floor E Jansen, Leanne Dibbens.   

Abstract

Dravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+) can both arise due to mutations of SCN1A, the gene encoding the alpha 1 pore-forming subunit of the sodium channel. GEFS+ refers to a familial epilepsy syndrome where at least two family members have phenotypes that fit within the GEFS+ spectrum. The GEFS+ spectrum comprises a range of mild to severe phenotypes varying from classical febrile seizures to Dravet syndrome. Dravet syndrome is a severe infantile onset epilepsy syndrome with multiple seizure types, developmental slowing and poor outcome. More than 70% of patients with Dravet syndrome have mutations of SCN1A; these include both truncation and missense mutations. In contrast, only 10% of GEFS+ families have SCN1A mutations and these comprise missense mutations. GEFS+ has also been associated with mutations of genes encoding the sodium channel beta 1 subunit, SCN1B, and the GABA(A) receptor gamma 2 subunit, GABRG2. The phenotypic heterogeneity that is characteristic of GEFS+ families is likely to be due to modifier genes. Interpretation of the significance of a SCN1A missense mutation requires a thorough understanding of the phenotypes in the GEFS+ spectrum whereas a de novo truncation mutation is likely to be associated with a severe phenotype. Early recognition of Dravet syndrome is important as aggressive control of seizures may improve developmental outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203856     DOI: 10.1016/j.braindev.2009.01.001

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  51 in total

Review 1.  SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome.

Authors:  Alex C Bender; Richard P Morse; Rod C Scott; Gregory L Holmes; Pierre-Pascal Lenck-Santini
Journal:  Epilepsy Behav       Date:  2012-02-16       Impact factor: 2.937

Review 2.  Axon initial segment dysfunction in epilepsy.

Authors:  Verena C Wimmer; Christopher A Reid; Eva Y-W So; Samuel F Berkovic; Steven Petrou
Journal:  J Physiol       Date:  2010-04-07       Impact factor: 5.182

Review 3.  Genetic evaluation and counseling for epilepsy.

Authors:  Deb K Pal; Amanda W Pong; Wendy K Chung
Journal:  Nat Rev Neurol       Date:  2010-07-20       Impact factor: 42.937

4.  Generalised epilepsy with febrile seizures plus (GEFS(+)): molecular analysis in a restricted area.

Authors:  Agata Polizzi; Gemma Incorpora; Piero Pavone; Martino Ruggieri; Grazia Annesi; Antonio Gambardella; Lorenzo Pavone; Aldo Quattrone
Journal:  Childs Nerv Syst       Date:  2011-10-20       Impact factor: 1.475

5.  Lack of replication of association between scn1a SNP and febrile seizures.

Authors:  S Petrovski; I E Scheffer; S M Sisodiya; T J O'Brien; S F Berkovic
Journal:  Neurology       Date:  2009-12-01       Impact factor: 9.910

Review 6.  The genetics of the epilepsies.

Authors:  Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

7.  Vaccination and the onset of dravet syndrome.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2011-07       Impact factor: 7.500

Review 8.  The sleep manifestations of frontal lobe epilepsy.

Authors:  Christopher P Derry
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

9.  Familial aggregation of focal seizure semiology in the Epilepsy Phenome/Genome Project.

Authors:  Steven Tobochnik; Robyn Fahlstrom; Catherine Shain; Melodie R Winawer
Journal:  Neurology       Date:  2017-05-31       Impact factor: 9.910

10.  Knock-in model of Dravet syndrome reveals a constitutive and conditional reduction in sodium current.

Authors:  Ryan J Schutte; Soleil S Schutte; Jacqueline Algara; Eden V Barragan; Jeff Gilligan; Cynthia Staber; Yiannis A Savva; Martin A Smith; Robert Reenan; Diane K O'Dowd
Journal:  J Neurophysiol       Date:  2014-05-07       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.